Navigation Links
Trius Appoints Paul Truex to Board of Directors
Date:6/1/2008

Industry veteran brings business development and transaction expertise

SAN DIEGO, June 2 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the appointment of Paul Truex to its Board of Directors. Truex is the founder, President and CEO of Anthera Pharmaceuticals. Previously he served as President and CEO of Peninsula Pharmaceuticals where he raised over $81 million of institutional capital (including $21000000 from a key strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co. Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million in an all cash transaction. Earlier in his career, Mr. Truex was Vice President of Commercial Development for Versicor (subsequently Vicuron which was acquired by Pfizer) where he directed early commercial efforts for infectious disease products and assisted with the company's successful IPO. Before Versicor he worked at Eli Lilly in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos(R) Evista(R) and Humalog 75/25(R)).

"It is with great pleasure that we welcome Paul to the Trius Board," said David Kabakoff, Ph.D., Chairman of the Board of Trius. "His business development and product commercialization experience in anti-infectives fit very well with Trius' stage of development and strategy."

"I look forward to working closely with the Trius Board and management team to help build and realize value," said Truex. "Their lead clinical stage drug, TR-701, as well as their preclinical programs will provide the company with compelling business opportunities."

The addition of Truex to Trius' Board completes a transition following Trius' $30 million Series B financing completed in March. At that time, Risa Stack, Ph.D. of Kleiner Perkins joined the Board. Former board members Julia Brown and Takashi Kiyoizumi, M.D., Ph.D. have joined Trius' Business Advisory Board. Brendan O'Leary, Ph.D., of Prism Ventures now serves as a Board Observer. "We are indebted to Ms. Brown and Drs. Kiyoizumi and O'Leary for their service on the Trius Board and are grateful for their continued contributions in their new roles," said Jeffrey Stein, Ph.D., President and CEO of Trius.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead drug candidate, TR-701 is a novel, oral and IV, oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pelikan Technologies Appoints Denny Ware to Board of Directors
2. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
3. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
4. Nventa Appoints Gordon H. Busenbark to Board of Directors
5. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
6. Informed Medical Communications Appoints New Chief Financial Officer
7. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
9. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
10. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
11. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... annual report which summarizes and analyzes nearly 750 unique supply chain notifications ... and analysis service. , Supply chain risk management practitioners subscribe to the ...
(Date:2/3/2016)... Feb. 3, 2016  Today, Symphony Technology Group (STG) ... , a leading provider of primary research and analytics-based ... IMS Health , a global information and technology services ... and technologies will be integrated into IMS Health to ... market research capabilities. ...
Breaking Biology Technology:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):